Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase... Read more.
University of Phoenix Continues to Empower Young Learners at Hackathon Jr. Event
University of Phoenix alumna, Dr. Rose Lorenzo, serves as CEO of Hackathon Jr. PHOENIX–(BUSINESS WIRE)–University of Phoenix is pleased to announce it... Read more.
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duration... Read more.
SVTA Announces New Board Officers
SVTA Welcomes New Members Yospace, Cadami, Akamai, and DAZN as Well as Numerous DASH-IF Members Participating in the Q3 Member Meeting in Antwerp, Belgium on September... Read more.
Irdeto Partners with Bitmovin to Deliver Industry-Leading Secure Low-Latency Streaming with Unmatched User Experience
This joint offering allows operators to benefit from seamless, high-quality streaming, extended device reach, and advanced advertising and security features AMSTERDAM–(BUSINESS... Read more.
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
KEYTRUDA is the first anti-PD-1/L1 therapy in combination with trastuzumab and chemotherapy to demonstrate a statistically significant improvement in OS in this... Read more.
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
Tumors shrank in 89% of taletrectinib-treated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who were tyrosine kinase inhibitor... Read more.
Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024
Updated monotherapy data for Nectin-4 targeting zelenectide pevedotin in metastatic urothelial cancer (mUC) showed a promising 45% overall response rate (ORR), 11.1... Read more.
Masimo Partners with Google to Develop a Reference Platform That Helps Device Manufacturers Bring High-performing Wear OS Smartwatches to Market
Comprehensive Smartwatch Reference Platform to Include Key Hardware and Software Components, Including Industry-leading Masimo Biosensing Capabilities IRVINE, Calif.–(BUSINESS... Read more.
SCF Acquires Newpark Fluids Systems
HOUSTON–(BUSINESS WIRE)–SCF Partners, Inc. (“SCF”) is pleased to announce its acquisition of the Newpark Fluids Systems business (“NFS”), a leading... Read more.